Company news
TransCode Therapeutics, Inc. news in 2023
TransCode Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 11, 2023
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 3, 2023
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
November 29, 2023
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
November 13, 2023
TransCode Therapeutics Withdraws Public Offering
October 29, 2023
TransCode Therapeutics Announces Public Offering of Common Stock
October 25, 2023
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
October 25, 2023
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
October 23, 2023
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
September 27, 2023
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
September 24, 2023
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
September 24, 2023
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
August 22, 2023
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
August 13, 2023
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
July 30, 2023
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
June 21, 2023
TransCode Therapeutics Announces Closing of $7 Million Public Offering
June 8, 2023
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
June 5, 2023
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
June 5, 2023
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
May 21, 2023
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 26, 2023
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
April 25, 2023
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
April 13, 2023
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
April 4, 2023
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
April 3, 2023
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
April 2, 2023
TransCode Therapeutics Reports 2022 Results; Provides Business Update
March 30, 2023
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
February 27, 2023
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
February 15, 2023
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
January 30, 2023